Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. [electronic resource]
Producer: 20071213Description: 5418-25 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor -- analysis
- Breast Neoplasms -- enzymology
- Cohort Studies
- Female
- Humans
- Immunohistochemistry -- methods
- Lymphatic Metastasis
- Middle Aged
- Protein Array Analysis -- methods
- Receptor, ErbB-2 -- analysis
- Receptors, Estrogen -- analysis
- Receptors, Progesterone -- analysis
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.